referred to the Retinal Diagnostic Department at this hospital which were amenable to photocoagulation and to identify those clinical attributes which may guide the clinician as to the likelihood of the lesion being suitable for photocoagulation. This information may give some indication about the management of disciform macular disease, and what the size of the clinical load might be if clinical trial shows this form of treatment to be justifiable.
Materials and methods
Fluorescein angiograms of all new non-diabetic patients referred to the Retinal Diagnostic Department of Moorfields Eye Hospital were examined retrospectively for the 12-month period from 1 December 1976 to 5 December 1977. Those angiograms which were found to have neovascular disciform lesions or pigment epithelial detachments were further subdivided according to the supposed aetiology of the disease.
Senile disciform degeneration was diagnosed in those patients over 50 years of age with drusen and pigment epithelial changes in addition to subretinal neovascularisation and in whom there was no evidence of other cause for their disease. The visual acuity and the duration of symptoms at the time of angiography were recorded for each affected eye.
Treatment by argon laser photocoagulation was considered possible in those eyes in which the sub-85 R. H. B. Grey, A. C. Bird, and I. H. Chisholm retinal neovascular membrane could be clearly defined and in which there was a discernible gap between the edge of the neovascular tissue and the foveola (about 100lm). The possibility of argon laser treatment at the time of angiography was related to the visual acuity and the duration of symptoms in affected eyes.
Patients in the older age group with pigment epithelial detachments associated with drusen were also identified, since these may precede the onset of vascular disciform lesions (Gass, 1967; Bird, 1 973b). All such lesions were considered potentially treatable.
All those patients who had had disciform degeneration for 3 years or more before angiography were analysed in order to identify the prognosis for visual acuity in untreated eyes.
Results
Two thousand non-diabetic patients were seen during the 12-month period of the study, and 530 eyes (398 patients) had subretinal neovascularisation ( Pigment epithelial detachments were found in 63 eyes in the group of patients with senile degeneration. These included both subfoveal and parafoveal detachments, and all were considered to be theoretically treatable except those in which the lesion was so small that photocoagulation would have involved the fovea.
Disciform lesions which had been present for 3 years or more had a better prognosis in the younger patients than in the elderly. Ten out of 15 younger patients (67%) had a final acuity of 6/60 or better and 5 (33%) had 6/24 or better. In the older group 24 out of 76 (32%) had 6/60 or better.
Discussion
The proportion of treatable lesions obtained in this series is not necessarily representative of disciform degeneration in the general ophthalmic outpatient population of this hospital owing to prior selection for fluorescein angiography; patients with longstanding disciform changes are less frequently investigated. Thus, in the eyes with senile neovascular changes the treatable number obtained here of 20% (30% including pigment epithelial detachments) may be too high in relation to the total numbei of patients with senile disciform disease presenting to the hospital clinics. On the other hand some eyes included in the study did not afford the primary reason for the patients' referral to us, since it was the fellow eye of one with recent visual loss. However, analysis of those patients who were considered treatable may offer useful guides to the clinician when trying to assess the likelihood of treatment being possible.
The chance of a disciform lesion being treatable may be predicted from the visual acuity alone. In this study an affected eye with an acuity of 6/24 or better had at least a 1 -in-3 chance of having a treatable lesion, but once the acuity had fallen to 6/60 or worse the chances were remote.
More important was the correlation between the proportion of treatable lesions in patients and the length of history of visual loss. 53% seen within 1 month were treatable, whereas the figure was only 15% when the symptoms had lasted over 4 months and 10% when over 1 year. This is not surprising, R. H. B. Grey, A. C. Bird, and I. H. Chishoim since progression is to be expected. Subretinal neovascular tissue, which originates eccentrically, has a tendency to expand, with a predilection for growth towards the fovea (Teeters and Bird, 1973b regained an acuity of 6/60 or better renders photocoagulation of the fovea difficult to justify.
It is relevant that a relatively large proportion of lesions were suitable for photocoagulation when seen early in their disease. There is no reason to believe that those seen early were different from those seen late, and it is likely that a much larger proportion of the latter group would have been treatable had they been seen earlier. The proportion of treatable lesions is encouraging, and is much higher than we expected. These figures imply that if photocoagulation proves to be an effective form of therapy it could be available to a large number of patients if systems of referral and assessment are speeded up.
The present justifiable demand that new therapeutic agents be assessed by controlled trial before they become accepted into routine medical practice gives rise to new problems in organising the delivery of health care. This is particularly important if the new form of treatment requires expensive equipment and additional staff. The treatment remains experimental before the trial is completed and yet if it is shown to be effective by trial it becomes justifiable and should be universally available. The former practice, which allowed the gradual evolution of new therapy over a period of decades, has been replaced by a situation where a rapid solution is required. The management of diabetic retinopathy recently proved (Diabetic Research Group, 1976; Cheng, 1976) illustrates the difficulties generated by the advent of clinical trials. Therefore, before a trial is completed, information is required on the natural history and population incidence of the disease in order to plan in advance the provision of the new therapy.
Clearly (Gregor et al., 1977) .
If controlled trial shows photocoagulation to be beneficial the clinical load which may be generated by disciform degeneration and its treatment will depend on its prevalence and the proportion of lesions likely to be treatable. There is no doubt that disciform macular degeneration is common. It has been estimated to account for 35,' (Sorsby, 1966) of the blind population in Caucasian societies, and the incidence of visible macular changes in the elderly of such societies is estimated as being 30% (Kornschweig et al., 1957) . The figures in this study suggest that photocoagulation may be justifiable in a large proportion of lesions, so that the additional clinical load could be great. Prompt referral and ready availability of treatment facilities will be ncessary to take advantage of this form of therapy. 
